IL179406A0 - Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors - Google Patents

Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors

Info

Publication number
IL179406A0
IL179406A0 IL179406A IL17940606A IL179406A0 IL 179406 A0 IL179406 A0 IL 179406A0 IL 179406 A IL179406 A IL 179406A IL 17940606 A IL17940606 A IL 17940606A IL 179406 A0 IL179406 A0 IL 179406A0
Authority
IL
Israel
Prior art keywords
imidazo
tetrahydro
synthase inhibitors
aldosterone synthase
pyridin derivatives
Prior art date
Application number
IL179406A
Other languages
English (en)
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of IL179406A0 publication Critical patent/IL179406A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL179406A 2004-05-28 2006-11-20 Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors IL179406A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH9152004 2004-05-28
PCT/EP2005/052419 WO2005118581A1 (en) 2004-05-28 2005-05-27 Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
IL179406A0 true IL179406A0 (en) 2007-05-15

Family

ID=34968588

Family Applications (2)

Application Number Title Priority Date Filing Date
IL179406A IL179406A0 (en) 2004-05-28 2006-11-20 Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors
IL179408A IL179408A0 (en) 2004-05-28 2006-11-20 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL179408A IL179408A0 (en) 2004-05-28 2006-11-20 Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors

Country Status (10)

Country Link
US (2) US20080076784A1 (enExample)
EP (2) EP1749005A1 (enExample)
JP (2) JP2008500997A (enExample)
CN (2) CN1968930A (enExample)
AR (2) AR049125A1 (enExample)
BR (2) BRPI0510409A (enExample)
CA (2) CA2568159A1 (enExample)
IL (2) IL179406A0 (enExample)
TW (2) TW200616623A (enExample)
WO (2) WO2005118581A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076784A1 (en) * 2004-05-28 2008-03-27 Peter Herold Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors
AR049667A1 (es) * 2004-07-09 2006-08-23 Speedel Experimenta Ag Heterociclos condensados conteniendo n como inhibidores de aromatasa y procedimiento para prepararlos
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
AR060225A1 (es) * 2006-03-31 2008-06-04 Speedel Experimenta Ag Proceso para preparar 6,7- dihidro-5h-imidazo (1,5-a) piridin -8- ona
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
PL2319923T3 (pl) * 2008-07-24 2014-05-30 Meiji Seika Pharma Co Ltd Geny biosyntezy pirypiropenu A
ES2745628T3 (es) * 2008-11-07 2020-03-03 Univ Sheffield Medicamento y método de diagnóstico
EP2426124B1 (en) 2009-05-13 2013-08-07 Meiji Seika Pharma Co., Ltd. Process for producing pyripyropene derivative
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
WO2011061168A1 (en) * 2009-11-17 2011-05-26 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
UA111151C2 (uk) 2010-03-01 2016-04-11 Мейдзі Сейка Фарма Ко., Лтд. Спосіб одержання похідних пірипіропену
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2013008164A2 (en) 2011-07-08 2013-01-17 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
CN103958478B (zh) * 2011-11-30 2017-08-01 霍夫曼-拉罗奇有限公司 双环二氢异喹啉‑1‑酮衍生物
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
RU2016116433A (ru) * 2013-10-17 2017-11-22 Ф. Хоффманн-Ля Рош Аг Новые производные фенил-дигидропиридина в качестве ингибиторов альдостерон синтазы
MX2016002762A (es) * 2013-10-17 2016-05-26 Hoffmann La Roche Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
US11179377B2 (en) 2017-03-10 2021-11-23 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US12209144B2 (en) 2018-11-27 2025-01-28 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
CN117659075B (zh) * 2023-12-18 2025-02-11 中国科学院兰州化学物理研究所 一种咪唑衍生型柱[5]芳烃手性填料的制备及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
JPH0670064B2 (ja) 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
JPH07503242A (ja) * 1992-01-27 1995-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アロマターゼ阻害剤としてのピロロイミダゾリルおよびイミダゾピリジニル置換１ｈ−ベンズイミダゾール誘導体
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
WO1997000257A1 (en) 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US6333335B1 (en) * 1999-07-23 2001-12-25 Merck & Co., Inc. Phenyl-protein transferase inhibitors
JP2001151696A (ja) * 1999-11-22 2001-06-05 Keiko Tanaka アクチニジンから造る腫瘍の増殖ならびに転移抑制酵素と異質なたんぱく細胞の除去剤
PL204934B1 (pl) * 2000-11-17 2010-02-26 Takeda Pharmaceutical Pochodne imidazolu i ich sole diastereomeryczne, kompozycje farmaceutyczne i środki do zmniejszania poziomu androgenu zawierające te pochodne oraz sposoby ich wytwarzania
US20080076784A1 (en) * 2004-05-28 2008-03-27 Peter Herold Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors
CN1956987A (zh) 2004-05-28 2007-05-02 斯皮德尔实验股份公司 杂环化合物及其作为醛固酮合酶抑制剂的应用
TW200608978A (en) 2004-05-28 2006-03-16 Speedel Experimenta Ag Organic compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds

Also Published As

Publication number Publication date
WO2005118540A2 (en) 2005-12-15
US8680079B2 (en) 2014-03-25
JP2008501000A (ja) 2008-01-17
US20080076784A1 (en) 2008-03-27
TW200616623A (en) 2006-06-01
TW200612947A (en) 2006-05-01
CN1960991A (zh) 2007-05-09
BRPI0510409A (pt) 2007-10-23
EP1765777A2 (en) 2007-03-28
CA2568159A1 (en) 2005-12-15
BRPI0511621A (pt) 2008-01-02
JP5179174B2 (ja) 2013-04-10
IL179408A0 (en) 2007-05-15
CN1968930A (zh) 2007-05-23
AR049126A1 (es) 2006-06-28
WO2005118540A3 (en) 2006-02-02
WO2005118581A1 (en) 2005-12-15
JP2008500997A (ja) 2008-01-17
US20070225232A1 (en) 2007-09-27
AR049125A1 (es) 2006-06-28
CA2568163A1 (en) 2005-12-15
EP1749005A1 (en) 2007-02-07

Similar Documents

Publication Publication Date Title
IL179406A0 (en) Tetrahydro-imidazo[1,5-a] pyridin derivatives as aldosterone synthase inhibitors
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
SI1966202T1 (sl) S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
ZA200809796B (en) Pyrazolo [1,5-A]pyrimidines as CDK inhibitors
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
ZA200806313B (en) Pyrrolo [3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors
PT2124944E (pt) Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
ZA200709919B (en) Pyrrol (2,3-B) pyridine derivatives protein kinase inhibitors
HK1102588A (en) Tetrahydro-imidazo (1,5-a) pyridin derivatives as aldosterone synthase inhibitors
HK1138515A (en) Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
HK1160846A (en) [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
HK1143578A (en) Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS